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Howick et al. have reported the findings of a survey that addressed the use of placebos among 
primary care practitioners in the United Kingdom. (1) They adopted methodology similar to that 
used in previous studies performed in other countries; however, the use of this approach also means 
that they repeated the conceptual confusion of the previous surveys. (2,3,4) Therefore the findings 
are not useful. 
First, although the authors acknowledge the conceptual problems related to placebos and placebo 
effects, they fail to consider the fundamental importance of these problems in their paper. They 
write for example: “... placebos are often characterized as inactive and nonspecific when in fact 
they can be active, and have specific effects, especially for relieving pain.” The essential difference 
between “giving a placebo” and “the placebo effect” (3,4) is not considered in their paper. 
By definition, a “placebo” means an inert substance. (5) The “placebo effect” is produced by other 
factors involved, such as expectancy, behavioral conditioning and the quality of the patient–
physician relationship, (6) but not by the inert placebo. Inert substances and methods cannot have  
“specific” – or “unspecific” – effects by themselves. Because of the misleading nature of the term 
“placebo effect”, other terms have been proposed to describe the phenomenon in clinical practice, 
including “care effect”, (3) “contextual healing”, (7) and “meaning response”. (8) 
Second, the authors wrote that they “adopted a pragmatic approach and asked physicians whether 
they used various treatments described as placebos in other similar surveys.” They justified this 
approach by claiming that their “approach has the advantage of being useful: patients, doctors, 
and policy makers care more about whether particular treatments are effective and ethical than 
whether these treatments carry the label ‘placebo’”. What the authors did, however, was to survey 
the frequency of the usage of placebos. Frequency of usage does not tell us anything about 
effectiveness, and it cannot act as a guide for policy makers about whether the “use of placebos” 
should be increased or decreased.
Third, the authors introduced a novel concept “ethical placebo” but did not elaborate it in any 
respect. At the end of their paper, they concluded that “further investigations are warranted to 
develop ethical and cost-effective placebos.” Given that, by definition, a “placebo” is inert, (5) 
it is not clear what the authors mean with their comment. Concealed use of inert substances or 
methods is deceiving and unethical. For example, the Council on Ethical and Judicial Affairs 
of the American Medical Association states that it “may undermine trust, compromise 
the patient–physician relationship, and result in medical harm to the patient”. (9)
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A few studies on the open-label use of placebos have indicated that a beneficial response is not 
necessarily limited to settings in which patients are deceived. (10,11,12) However, open-label use 
of pure placebos remains a special case, and no general recommendations can yet be given. 
Problems related to so-called impure placebos are described below.
Fourth, the only findings of the survey that make any sense are the figures describing the use of 
“pure placebos”. However, even in this respect the findings leave many questions open. The authors 
wrote that pure placebos mean “interventions such as sugar pills ... or saline injections without 
direct pharmacologically active ingredients for the condition being treated.” The questionnaire 
asked “respondents to note how frequently (if at all) they used placebo interventions”. According to 
the results, 12% of the respondents reported using pure placebos at least once in their career. 
It is not clear what the term “using” covered. Did the respondents mean 1) writing a formal 
prescription for a pure placebo without informing the patient that the physician believed it to be 
pharmacologically ineffective, 2) giving the patient pure placebos directly from the physician’s 
office, 3) verbally suggesting that the patient might test a treatment the physician considered 
ineffective, or 4) allowing the patient to use, for example, alternative medicine treatments that 
the physician considered useless. All of these four options are very different types of situations, 
and some are clearly unethical, whereas some are less so. (2) Furthermore, even though 12% of 
the respondents reported using pure placebos at least once in their career, only 0.9% reported using 
them frequently. Since the use of pure placebos implies the misleading of patients, and misleading 
patients is unethical, (9) we conclude that less than 1% of general practitioners in the UK are 
frequently unethical in this sense.
Fifth, the authors adopted the concept “impure placebo” uncritically from earlier research, and they 
ignored the confusion created by the use of this concept in empirical studies. (2) They defined 
impure placebos as “substances, interventions or ‘therapeutic’ methods which have known 
pharmacological, clinical or physical value for some ailments but lack specific therapeutic effects 
or value for the condition for which they have been prescribed”. They gave examples of impure 
placebos, such as positive suggestions, probiotics for diarrhea, antibiotics for suspected viral 
infections, off-label uses of potentially effective therapies, conventional medicine whose 
effectiveness is not evidence-based, non-essential physical examinations, and non-essential 
technical examinations of the patient (blood tests, X-rays). Their list had a few more items, 
and, at the bottom of Table 2, they gave 11 more items that they classified as “impure placebos”.
We cannot see any justification for classifying all the preceding examples under the singular 
heading of “impure placebo”, let alone classifying all of them together with the “pure placebos” 
under the higher level heading “placebos”. All of their examples are problematic in some sense. 
To save space, we will not comment on all two dozen items in the authors' lists, but a few examples 
follow: 
a) Positive suggestions
Utterances like “you will certainly feel better in a few days” belong to normal good physician–
patient relationships and do not “lack ... value for the condition for which they have been 
prescribed”. 
b) Probiotics for diarrhea 
There is evidence that probiotics have preventive, as well as curative, effects on some types 
of diarrhea (13,14). Why have the authors ignored this evidence?
c) Antibiotics for suspected viral infections
Most respiratory infections are viral in origin, but laboratory tests are seldom made to confirm 
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the etiology. Many patients have both viruses and bacteria simultaneously, and it is usually not 
possible to determine for certain whether antibiotics are ineffective. (4,15,16) A decision to 
prescribe antibiotics is often based on the probability of bacterial infection, and the duration of 
symptoms is one of the associated factors that physicians consider. Thus the use of antibiotics 
for acute respiratory tract infections cannot be classified uniformly as placebo treatment.
d) Off-label uses of potentially effective therapies
The official process of approving pharmaceuticals has legal and commercial components, and it is 
only partly based on scientific evidence. Off-label use – prescribing for an unapproved indication or 
an unapproved age group – is common practice, for example, in pediatrics and intensive care. There 
is no justification to classify off-label treatments as placebo interventions. 
e) Conventional medicine whose effectiveness is not evidence-based 
“Evidence-based medicine” (EBM) is a problematic term that dichotomizes medicine artificially 
into two fields: EBM and non-EBM. There are many definitions of EBM, but they are vague and do 
not provide an unambiguous demarcation line between the EBM and non-EBM sectors of medicine. 
We agree with Timmermans and Mauck, who noted that “The term is loosely used and can refer to 
anything from conducting a statistical meta-analysis of accumulated research, to promoting 
randomized clinical trials, to supporting uniform reporting styles for research, to a personal 
orientation toward critical self-evaluation.” (17) Thus the EBM or non-EBM division is irrelevant 
to the question of what is or is not a placebo.
f) Non-essential physical examinations and non-essential technical examinations of a patient 
(blood tests, X-rays)
It is often not obvious what physical or technical examinations are useful for a particular patient. 
All experienced physicians recall cases in which an examination that originally seemed non-
essential unexpectedly revealed important findings. In some cases, it is the pressure of the patient 
that leads to an examination or X-ray being made. It is not reasonable to classify such examinations 
as placebo interventions.
In conclusion, the paper’s main finding “placebos are commonly used in UK primary care” is not 
correct. Only 0.9% of the responding general practitioners reported using pure placebos frequently. 
The frequency with which impure placebos are used is irrelevant because the concept is useless, as 
described above.  
Misleading a patient by administering inert substances without the explicit consent of the patient is 
unethical. The authors' proposal to “develop ethical and cost-effective placebos” is not possible 
because saving money by misleading patients is unethical. There is substantial conceptual confusion 
in the area of placebo and placebo-effect research, and the paper by Howick et al. does not help to 
reduce this confusion. 
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